The Department of Justice filed the lawsuit in the U.S. District Court for the District of Columbia to stop the deal just ahead of it being finalized on February 27.
ViVE 2022, powered by HLTH and CHIME, will convene top thought leaders who are shaping tech-enabled healthcare and addressing key issues in digital health innovation. Save $150 with code medcity150!
We are extending our INVEST 2022 Pitch Perfect deadline to Feb 11, 11:59 p.m. ET to allow interested startups to apply to the 4 tracks - PharmaTech, Diagnostics 2.0, Care Coordination and Value-Based Care, and Remote Patient Monitoring and Smart Devices. Slots are going fast so we encourage all startups - particularly those interested to apply in the PharmaTech and Diagnostics tracks to apply immediately. Selected startups will get to pitch LIVE on stage in front of VC judges. Here's the agenda for the INVEST conference.
By Frank Vinluan Thursday, February 24, 2022 6:58 PM
New startup hC Bioscience is developing therapies based on transfer RNA, molecules that can be leveraged to address disease-causing proteins. The biotech joins several companies that are developing tRNA therapies in this emerging class of genetic medicines.
By Michael Schroeder Thursday, February 24, 2022 6:40 PM
The financial terms of the three-year deal were not disclosed. Beginning in Q3, NeuroFlow will be available to new and existing clients that have fully insured group long-term disability policies through Aflac with more than 1,000 covered lives, according to the agreement.
By MedCity News Thursday, February 24, 2022 2:59 PM
MedCity News is bringing its INVEST Digital Health conference to Dallas on September 28. Every year we will discuss something that's new and emerging in healthcare – this year, it will be the Metaverse – while also taking a closer look at the trends in the employer and consumer worlds.
By Frank Vinluan Thursday, February 24, 2022 1:25 PM
The SPAC merger that Amicus Therapeutics planned for its gene therapy assets has been called off due to market conditions. The rare disease company is instead keeping those assets but streamlining its portfolio in order to save $400 million—the amount that the gene therapy spinout was in line to receive from the merger deal.
By Paul Jaglowski Thursday, February 24, 2022 12:11 PM
Patient expectations are drastically changing due to the pandemic, access to technology and generational preferences. By actively listening to patients and drawing on data healthcare organizations already have, it's possible to personalize experiences and improve care delivery.
No comments